August 26, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys™, its trastuzumab biosimilar version. Earlier in July 2025, Dazublys™ has received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ's fourth biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025 and Dyrupeg™ in June 2025. Dazublys™, Zefylti™, and Dyrupeg™ are also approved in the European Union.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.08.26 09:27:19 +05'30'

B. Adi Reddy
Company Secretary